Insilico Medicine, a leader in clinical-stage generative AI for drug discovery, announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform,...
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with...
AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas.
Insilico Medicine, a clinical-stage biotechnology company powered by generative...
Fresh off its landmark December 2025 listing on the Hong Kong Stock Exchange, Insilico Medicine has inked a multi-year R&D collaboration with global pharma...
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully secured a $110 million Series E financing led...
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico...
The research demonstrates a breakthrough in applying quantum-enhanced generative AI to drug discovery using today’s quantum devices.
Zapata Computing, Inc., the Industrial Generative AI company,...